<span item_type="fundamental" item_id="a27518234d89692eca9805d19a05abac" counter_id="ST/US/RVPHW" env="prod"></span><span item_type="announcement" item_id="516466046123970177" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.13.</p><p></p><h3>Financial Results for March 31, 2025</h3><h4>Net Loss</h4><p>The company reported a net loss of approximately $6.4 million, or $0.13 per share, for the three months ended March 31, 2025, compared to a net loss of approximately $7.4 million, or $0.25 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm"></span></p><h4>Cash and Cash Equivalents</h4><p>As of March 31, 2025, the company’s cash and cash equivalents totaled approximately $5.3 million, a decrease from approximately $13.5 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm"></span></p><h4>Operating Expenses</h4><p>Total operating expenses for the three months ended March 31, 2025, were $6.5 million, down from $7.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm"></span></p><h4>Research and Development Expenses</h4><p>These expenses were $4.1 million for the three months ended March 31, 2025, compared to $5.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm"></span></p><h4>General and Administrative Expenses</h4><p>These expenses were $2.4 million for the three months ended March 31, 2025, compared to $2.1 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm"></span></p><h3>Outlook / Guidance</h3><p>Reviva Pharmaceuticals Holdings, Inc. anticipates the initiation of the registrational Phase 3 RECOVER-2 trial for brilaroxazine in mid-2025, subject to additional financing. The company is targeting a potential New Drug Application (NDA) submission for brilaroxazine in the fourth quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/ex_818734.htm"></span></p>

Reviva Pharmaceuticals - CW23 | 8-K: FY2025 Q1 EPS: USD -0.13